Stockreport
PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion [Yahoo! Finance]
Last verisk analytics, inc. earnings: 2/18 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations: investor.verisk.com/overview/default.aspx
Technologies, Inc. ( OTC: BSEM ). Following a successful start to 2024, the biotechnology company has seen substantial revenue growth and is making significant strides towards consolidating its debt, pursuing a potential uplisting to a senior stock exchange, and launching pivotal clinical trials. BioStem Technologies reported a remarkable increase in first-quarter revenues to $41.9 million in 2024, up from $600,000 in the same period last year, marking a pivotal milestone in the company's financial performance. "The first quarter of 2024 has been phenomenal," Jason Matuszewski, CEO of BioStem, explained. The company has also transitioned into a net positive equity position, reporting positive net income on a US GAAP basis for the first time. Looking ahead, BioStem is focused on sustainable growth by expanding its product offerings and geographical presence in the hospital wound care and other medical settings. "Our strategic direction is clear as we move towards 2025," Matuszewski
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | VRSK | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
VRSK alerts
VRSK alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRSK alerts
High impacting Verisk Analytics, Inc. news events
Weekly update
A roundup of the hottest topics
VRSK
NEWS
NEWS
- CORRECTION: John Routhier Joins SNH Capital Partners as Operating Partner to Drive Revenue Strategies and Portfolio Growth [Yahoo! Finance][Yahoo! Finance]
- Verisk Analytics, Inc. (NASDAQ: VRSK) had its price target raised by analysts at Barclays PLC from $275.00 to $310.00. They now have an "overweight" rating on the stock.[MarketBeat]
- Strong Results Lifted Verisk Analytics (VRSK) in Q2 [Yahoo! Finance][Yahoo! Finance]
- Are Verisk Analytics, Inc. (NASDAQ:VRSK) Investors Paying Above The Intrinsic Value? [Yahoo! Finance][Yahoo! Finance]
- Aclarion Added to PRISM Emerging Medical Devices Index [Yahoo! Finance][Yahoo! Finance]
- More
VRSK
SEC Filings
SEC Filings
- 9/17/24 - Form 4
- 9/16/24 - Form 144
- 8/30/24 - Form 4
- VRSK's page on the SEC website
- More